keyword
https://read.qxmd.com/read/38722422/aso-author-reflections-which-was-the-better-regimen-gemcitabine-plus-nab-paclitaxel-versus-gemcitabine-plus-s-1-as-neoadjuvant-chemotherapy-for-localized-pancreatic-ductal-adenocarcinoma-r-br-pdac
#1
JOURNAL ARTICLE
Daisaku Yamada, Shogo Kobayashi, Hidenori Takahashi, Yoshifumi Iwagami, Hirofumi Akita, Kei Asukai, Junzo Shimizu, Terumasa Yamada, Masahiro Tanemura, Shigekazu Yokoyama, Masanori Tsujie, Tadafumi Asaoka, Yutaka Takeda, Osakuni Morimoto, Akira Tomokuni, Yuichiro Doki, Hidetoshi Eguchi
No abstract text is available yet for this article.
May 9, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38722221/j-avenue-a-retrospective-real-world-study-evaluating-patient-characteristics-and-outcomes-in-patients-with-advanced-urothelial-carcinoma-treated-with-avelumab-first-line-maintenance-therapy-in-japan
#2
JOURNAL ARTICLE
Eiji Kikuchi, Nozomi Hayakawa, Masashi Nakayama, Masahiro Uno, Hiroomi Nakatsu, Chiyoe Kitagawa, Hideaki Miyake, Takeshi Yamada, Kazutoshi Fujita, Hideaki Shimoyama, Kiyoaki Nishihara, Mizuki Kobayashi, Motonobu Nakamura, Kiyohide Fujimoto, Takeshi Sano, Naotaka Nishiyama, Takayuki Ito, Masahiro Kajita, Takashi Kobayashi, Hiroshi Kitamura
OBJECTIVES: The JAVELIN Bladder 100 phase 3 trial showed that avelumab first-line maintenance + best supportive care significantly prolonged overall survival and progression-free survival versus best supportive care alone in patients with advanced urothelial carcinoma who were progression-free following first-line platinum-based chemotherapy. We report findings from J-AVENUE (NCT05431777), a real-world study of avelumab first-line maintenance therapy in Japan. METHODS: Medical charts of patients with advanced urothelial carcinoma without disease progression following first-line platinum-based chemotherapy, who received avelumab maintenance between February and November 2021, were reviewed...
May 9, 2024: International Journal of Urology: Official Journal of the Japanese Urological Association
https://read.qxmd.com/read/38720356/cannabidiol-s-cytotoxicity-in-pancreatic-cancer-is-induced-via-an-upregulation-of-ceramide-synthase-1-and-er-stress
#3
JOURNAL ARTICLE
Nagina Mangal, Vikash Reebye, Nagy Habib, Mikael H Sodergren
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a median 5 year-survival rate of 12%. Cannabidiol (CBD) has been found to exhibit antineoplastic potential and may potentiate the anticancer effects of cytotoxic's such as gemcitabine. CBD therapy has been linked to de novo synthesis of ceramide. The sphingolipid ceramide is a potent tumour suppressor lipid with roles in apoptosis and autophagy. One of the key players involved is ceramide synthase, an enzyme with six isoforms (CerS1-CerS6), reported to have disease prognostic value...
May 8, 2024: Journal of cannabis research
https://read.qxmd.com/read/38720294/rutinosides-derived-from-sarocladium-strictum-6-o-%C3%AE-rhamnosyl-%C3%AE-glucosidase-show-enhanced-anti-tumoral-activity-in-pancreatic-cancer-cells
#4
JOURNAL ARTICLE
Gisela Weiz, Alina L González, Iara S Mansilla, Martín E Fernandez-Zapico, María I Molejón, Javier D Breccia
BACKGROUND: Low targeting efficacy and high toxicity continue to be challenges in Oncology. A promising strategy is the glycosylation of chemotherapeutic agents to improve their pharmacodynamics and anti-tumoral activity. Herein, we provide evidence of a novel approach using diglycosidases from fungi of the Hypocreales order to obtain novel rutinose-conjugates therapeutic agents with enhanced anti-tumoral capacity. RESULTS: Screening for diglycosidase activity in twenty-eight strains of the genetically related genera Acremonium and Sarocladium identified 6-O-α-rhamnosyl-β-glucosidase (αRβG) of Sarocladium strictum DMic 093557 as candidate enzyme for our studies...
May 8, 2024: Microbial Cell Factories
https://read.qxmd.com/read/38719932/selective-but-not-pan-cdk-inhibition-abrogates-5-fu-driven-tissue-factor-upregulation-in-colon-cancer
#5
JOURNAL ARTICLE
Annika Kayser, Annabell Wolff, Peggy Berlin, Lara Duehring, Larissa Henze, Ralf Mundkowski, Wendy Bergmann, Brigitte Müller-Hilke, Charlotte Wagner, Maja Huehns, Sonja Oehmcke-Hecht, Claudia Maletzki
Thromboembolic events are complications in cancer patients and hypercoagulability has been linked to the tissue factor (TF) pathway, making this an attractive target. Here, we investigated the effects of chemotherapeutics and CDK inhibitors (CDKI) abemaciclib/palbociclib (CDK4/6), THZ-1 (CDK7/12/13), and dinaciclib (CDK1/2/5/9) alone and in combination regimens on TF abundance and coagulation. The human colorectal cancer (CRC) cell line HROC173 was treated with 5-FU or gemcitabine to stimulate TF expression...
May 8, 2024: Scientific Reports
https://read.qxmd.com/read/38718846/ches1-modulated-tumorigenesis-and-senescence-of-pancreas-cancer-cells-through-repressing-akr1b10
#6
JOURNAL ARTICLE
Demin Kong, Yingying Wu, Binghua Tong, Yonghui Liang, Fuyi Xu, Xiaodong Chi, Lei Ni, Geng Tian, Guilong Zhang, Zhaowei Xu
Pancreatic ductal adenocarcinoma (PDAC), is characteristic by a heterogeneous tumor microenvironment and gene mutations, conveys a dismal prognosis and low response to chemotherapy and immunotherapy. Here, we found that checkpoint suppressor 1 (CHES1) served as a tumor repressor in PDAC and was associated with patient prognosis. Functional experiments indicated that CHES1 suppressed the proliferation and invasion of PDAC by modulating cellular senescence. To further identify the downstream factor of CHES1 in PDAC, label-free quantitative proteomics analysis was conducted, which showed that the oncogenic Aldo-keto reductase 1B10 (AKR1B10) was transcriptionally repressed by CHES1 in PDAC...
May 6, 2024: Biochimica et Biophysica Acta. Molecular Basis of Disease
https://read.qxmd.com/read/38714516/risk-factors-for-failing-to-complete-gemcitabine-cisplatin-neoadjuvant-chemotherapy-in-muscle-invasive-bladder-cancer-patients
#7
JOURNAL ARTICLE
Homin Kang, Jungyo Suh, Dalsan You, In Gab Jeong, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Bumjin Lim
PURPOSE: We evaluated the risk factors associated with failure to complete gemcitabine-cisplatin (GP) neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: In total, 231 patients with MIBC treated with NAC before undergoing radical cystectomy between 2013 and 2022 participated in this study. Logistic regression analysis was performed to assess the relationship between the likelihood of incomplete NAC and clinical and demographic variables, including age, sex, hypertension (HTN), diabetes mellitus (DM), prechemotherapy glomerular filtration rate, clinical T stage, clinical N stage, and body mass index (BMI)...
May 2024: Investigative and Clinical Urology
https://read.qxmd.com/read/38714515/comparative-analysis-of-recurrence-rates-between-intravesical-gemcitabine-and-bacillus-calmette-gu%C3%A3-rin-induction-therapy-following-transurethral-resection-of-bladder-tumors-in-patients-with-intermediate-and-high-risk-bladder-cancer-a-retrospective-multicenter
#8
MULTICENTER STUDY
Joongwon Choi, Kyung Hwan Kim, Hyung Suk Kim, Hyun Sik Yoon, Jung Hoon Kim, Jin Wook Kim, Yong Seong Lee, Se Young Choi, In Ho Chang, Young Hwii Ko, Wan Song, Byong Chang Jeong, Jong Kil Nam
PURPOSE: This study investigated the efficacy of intravesical gemcitabine as an alternative to bacillus Calmette-Guérin (BCG) therapy. MATERIALS AND METHODS: Data were retrospectively collected across seven institutions from February 1999 to May 2023. Inclusion criteria included patients with intermediate- or high-risk non-muscle invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumors (TURBT) and received at least four sessions of intravesical gemcitabine or BCG induction therapy...
May 2024: Investigative and Clinical Urology
https://read.qxmd.com/read/38711136/adjuvant-chemotherapy-omission-after-pancreatic-cancer-resection-a-french-nationwide-study
#9
JOURNAL ARTICLE
Charles Poiraud, Xavier Lenne, Amélie Bruandet, Didier Theis, Nicolas Bertrand, Anthony Turpin, Stephanie Truant, Mehdi El Amrani
BACKGROUND: Adjuvant chemotherapy (AC) improves the prognosis after pancreatic ductal adenocarcinoma (PDAC) resection. However, previous studies have shown that a large proportion of patients do not receive or complete AC. This national study examined the risk factors for the omission or interruption of AC. METHODS: Data of all patients who underwent pancreatic surgery for PDAC in France between January 2012 and December 2017 were extracted from the French National Administrative Database...
May 6, 2024: World Journal of Surgical Oncology
https://read.qxmd.com/read/38711003/correction-to-a-phase-ii-iii-randomized-clinical-trial-of-cisplatin-plus-gemcitabine-and-nabpaclitaxel-gap-as-preoperative-chemotherapy-versus-immediate-resection-in-patients-with-resectable-biliary-tract-cancers-btc-at-high-risk-for-recurrence-purity-study
#10
Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano, Federica Palermo, Lorenza Rimassa, Tiziana Pressiani, Rossana Berardi, Andrea Casadei Gardini, Elisa Sperti, Lisa Salvatore, Davide Melisi, Francesca Bergamo, Salvatore Siena, Stefania Mosconi, Rafaella Longarini, Giuseppina Arcangeli, Salvatore Corallo, Laura Delliponti, Stefano Tamberi, Elena Fea, Giovanni Brandi, Ilario Giovanni Rapposelli, Massimiliano Salati, Paolo Baili, Rosalba Miceli, Silva Ljevar, Ilaria Cavallo, Elisa Sottotetti, Antonia Martinetti, Michele Droz Dit Busset, Carlo Sposito, Maria Di Bartolomeo, Filippo Pietrantonio, Filippo de Braud, Vincenzo Mazzaferro
No abstract text is available yet for this article.
May 6, 2024: BMC Cancer
https://read.qxmd.com/read/38709202/a-novel-anoikis-related-signature-predicts-prognosis-risk-and-treatment-responsiveness-in-diffuse-large-b-cell-lymphoma
#11
JOURNAL ARTICLE
Mingze Guan, Hua Zhao, Qi Zhang, Li Li, Xiaobo Wang, Bo Tang
BACKGROUND: Although anoikis plays a role in cancer migration, metastasis, and aggressiveness, it has rarely been reported in diffuse large B cell lymphoma (DLBCL). METHODS: We obtained RNA sequencing data and matched clinical data from the GEO database. An anoikis-related genes (ARGs)-based risk signature was developed using univariate Cox regression and LASSO regression in GSE10846 training cohort, and was validated in three other cohorts. The expression of candidate genes of the ARG signature was validated by RT-qPCR...
May 6, 2024: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38706910/ultrasound-targeted-microbubble-destruction-improves-the-suppression-and-magnetic-resonance-imaging-of-pancreatic-cancer-with-polyethyleneimine-nanogels
#12
JOURNAL ARTICLE
Yang Liu, Yuanqiong Deng, Paul E Constanthin, Fan Li
The chemoresistance of pancreatic cancer tumors urgently needs to be addressed. Pancreatic cancer is characterized by an abundant stroma, with significant fibrous connective tissue formation that encapsulates the tumor parenchyma and forms an interstitial microenvironment. Pancreatic stellate cells (PSCs) play a crucial role in this microenvironment and specially secrete periosteal protein (periostin), which can promote tumor growth, metastasis, and chemoresistance. Therefore, periostin has become a specific target of chemotherapy resistance intervention methods...
2024: Journal of Cancer
https://read.qxmd.com/read/38706841/fasting-induced-rnf152-resensitizes-gallbladder-cancer-cells-to-gemcitabine-by-inhibiting-mtorc1-mediated-glycolysis
#13
JOURNAL ARTICLE
Ying Tao, Zijun Gong, Sheng Shen, Yaqi Ding, Rui Zan, Bohao Zheng, Wentao Sun, Chaolin Ma, Mengxuan Shu, Xiao Lu, Han Liu, Xiaoling Ni, Houbao Liu, Tao Suo
Abnormal mTORC1 activation by the lysosomal Ragulator complex has been implicated in cancer and glycolytic metabolism associated with drug resistance. Fasting upregulates RNF152 and mediates the metabolic status of cells. We report that RNF152 regulates mTORC1 signaling by targeting a Ragulator subunit, p18, and attenuates gemcitabine resistance in gallbladder cancer (GBC). We detected levels of RNF152 and p18 in tissues and undertook mechanistic studies using activators, inhibitors, and lentivirus transfections...
May 17, 2024: IScience
https://read.qxmd.com/read/38704133/bet-inhibition-decreases-hmgcs2-and-sensitizes-resistant-pancreatic-tumors-to-gemcitabine
#14
JOURNAL ARTICLE
Aubrey L Miller, Samuel C Fehling, Rebecca B Vance, Dongquan Chen, Eric Josh Brown, M Iqbal Hossain, Eric O Heard, Shaida Andrabi, Hengbin Wang, Eddy S Yang, Donald J Buchsbaum, Robert C A M van Waardenburg, Susan L Bellis, Karina J Yoon
Efforts to develop targetable molecular bases for drug resistance for pancreatic ductal adenocarcinoma (PDAC) have been equivocally successful. Using RNA-seq and ingenuity pathway analysis we identified that the superpathway of cholesterol biosynthesis is upregulated in gemcitabine resistant (gemR) tumors using a unique PDAC PDX model with resistance to gemcitabine acquired in vivo. Analysis of additional in vitro and in vivo gemR PDAC models showed that HMG-CoA synthase 2 (HMGCS2), an enzyme involved in cholesterol biosynthesis and rate limiting in ketogenesis, is overexpressed in these models...
May 2, 2024: Cancer Letters
https://read.qxmd.com/read/38702396/the-evolving-treatment-landscape-of-metastatic-urothelial-cancer
#15
REVIEW
Giandomenico Roviello, Matteo Santoni, Guru P Sonpavde, Martina Catalano
Cisplatin-based chemotherapy is currently the first-line standard of care for patients with metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for cisplatin, necessitating alternative treatment options. Immune checkpoint inhibitors have been shown to be effective in cisplatin-ineligible patients. However, despite advances in the first-line setting, the prognosis remains poor, and challenges persist in selecting optimal therapies, treatment sequences and combination regimens. Maintenance therapy with avelumab revealed improved overall (OS) and progression-free survival (PFS) compared with best supportive care alone in patients with platinum-responsive mUC...
May 3, 2024: Nature Reviews. Urology
https://read.qxmd.com/read/38702394/aso-visual-abstract-skeletal-muscle-derived-irisin-enhances-gemcitabine-sensitivity-and-suppresses-migration-ability-in-pancreatic-ductal-adenocarcinoma
#16
JOURNAL ARTICLE
Tomoki Sugimoto, Yoshifumi Iwagami, Shogo Kobayashi, Chihiro Yamanaka, Kazuki Sasaki, Daisaku Yamada, Yoshito Tomimaru, Tadafumi Asaoka, Takehiro Noda, Hidenori Takahashi, Junzo Shimizu, Yuichiro Doki, Hidetoshi Eguchi
No abstract text is available yet for this article.
May 3, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38701869/helicobacter-pylori-infection-induces-pou5f1-upregulation-and-spp1-activation-to-promote-chemoresistance-and-t-cell-inactivation-in-gastric-cancer-cells
#17
JOURNAL ARTICLE
Hanyi Song, Xinjie Yao, Yuqi Zheng, Long Zhou
Infection with Helicobacter pylori (H. pylori or Hp) is associated with an increased susceptibility to gastric diseases, notably gastric cancer (GC). This study investigates the impact of Hp infection on chemoresistance and immune activity in GC cells. Hp infection in AGS and MKN-74 cells promoted proliferation, migration and invasion, apoptosis resistance, and tumorigenic activity of cells under cisplatin (DDP) plus gemcitabine (GEM) treatment. Additionally, it dampened activity of the co-cultured CD8+ T cells...
May 1, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38701267/identification-of-cuproptosis-related-long-non-coding-rna-and-construction-of-a-novel-prognostic-signature-for-bladder-cancer-an-observational-study
#18
JOURNAL ARTICLE
Zegen Ye, Chunhua Liu, Simin Wu, Xinxin Jin, Huajian Lin, Tingting Wang, Qiuxia Zheng, Zhaofu Guo
Bladder Urothelial Carcinoma (BLCA), a prevalent and lethal cancer, lacks understanding regarding the roles and prognostic value of cuproptosis-related lncRNAs (CRLs), a novel form of cell death induced by copper. We collected RNA-seq data, clinical information, and prognostic data for 414 BLCA samples and 19 matched controls from The Cancer Genome Atlas. Using multivariate and univariate Cox regression analyses, we identified CRLs to create a prognostic signature. Patients were then divided into low- and high-risk groups based on their risk scores...
May 3, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38698688/analysis-of-chemoresistance-characteristics-and-prognostic-relevance-of-postoperative-gemcitabine-adjuvant-chemotherapy-in-pancreatic-cancer
#19
JOURNAL ARTICLE
Jiaqiang Ren, Shuai Wu, Tong Su, Jiachun Ding, Fan Chen, Jie Li, Zheng Wang, Liang Han, Zheng Wu
AIM: To investigate the relationship between chemoresistance in pancreatic cancer patients receiving postoperative gemcitabine adjuvant therapy and specific clinical/pathological characteristics, as well as its impact on patient prognosis. METHODS: From June 2018 to June 2021, clinical and pathological data of 148 pancreatic cancer patients were collected, and 101 patients were followed up for tumor recurrence/metastasis and survival status. The correlation between chemoresistance and specific clinical/pathological characteristics or patient prognosis was retrospectively analyzed...
May 2024: Cancer Medicine
https://read.qxmd.com/read/38697678/efficacy-of-dual-checkpoint-inhibitors-in-a-patient-with-a-mixed-hepatocellular-cholangiocarcinoma
#20
JOURNAL ARTICLE
Santiago Sucre, Andrea Bullock, Mary Linton Peters
A woman in her 60s was diagnosed with a metastatic, unresectable rare histological type of liver cancer; combined hepatocellular cholangiocarcinoma. She had palliative chemotherapy, initially with gemcitabine and cisplatin, and then with oxaliplatin, L-folinic acid and fluorouracil. Both treatment strategies demonstrated disease progression, and somatic mutation profiling revealed no actionable mutations. The patient was started on immuno-oncology (IO) with nivolumab and ipilimumab, followed by maintenance nivolumab...
May 2, 2024: BMJ Case Reports
keyword
keyword
40281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.